ストックスクリーナーアプリを入手
4.77
1.45%
-0.07
前日終値:
$4.84
開ける：
$4.8
24時間の取引高:
5,653
Relative Volume:
0.03
時価総額：
$685.78M
収益：
$31.37M
当期純損益:
$-53.77M
株価収益率:
-3.2813
EPS:
-1.4537
ネットキャッシュフロー:
$-49.02M
1週間 パフォーマンス:
+9.15%
1か月 パフォーマンス:
+43.67%
6か月 パフォーマンス:
-31.95%
1年 パフォーマンス:
-78.32%
1日の値動き範囲:
$4.76
$4.84
1週間の範囲:
$4.36
$5.20
52週間の値動き範囲:
$1.97
$22.71
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
名前
Silence Therapeutics Plc Adr
セクター
電話
44-0-20-3457 6900
住所
72 HAMMERSMITH ROAD, LONDON
SLN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
4.84 | 189.39M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
ONC
Beigene Ltd Adr
|
239.98 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.73 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.33 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.87 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.52 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-11 | 開始されました | Goldman | Sell |
| 2024-12-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2024-09-03 | 開始されました | Jefferies | Buy |
| 2024-01-31 | 開始されました | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr (SLN) 最新ニュース
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics stock hits 52-week low at $3.19 By Investing.com - Investing.com South Africa
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - MSN
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn - Investing.com
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn By Investing.com - Investing.com South Africa
Taiwan Semiconductor Valuation: How Realistic Is the Price? - The Globe and Mail
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges - Investing.com
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Goldman Sachs cuts Silence Therapeutics stock rating to Sell By Investing.com - Investing.com South Africa
Should investors be concerned about Silence Therapeutics Plc ADR (SLN)? - US Post News
Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex
Cloudflare Inc’s (NET) Stock: A 29.10% Simple Moving Average for the Past 20 Days - The News Heater
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. WAINWRIGHT MAINTAINS $75 TARGET ON SILENCE THERAPEUTICS STOCK By Investing.com - Investing.com South Africa
European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Silence Therapeutics' SWOT analysis: stock's potential in RNAi therapeutics - Investing.com
Silence Therapeutics' SWOT analysis: RNAi stock poised for growth amid clinical progress - Investing.com India
Silence Therapeutics announces additional results from SANRECO study - TipRanks
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - MSN
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India
Silence Therapeutics weakness after AHA updates ‘overdone,’ says BMO Capital - TipRanks
SILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes - TipRanks
Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga
Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Silence Therapeutics: Rising Assets Amid Growing Losses - TipRanks
Biogen's Lupus Candidate Meets Key Goals in Phase III Study - Yahoo Finance
The 3 Best Gene Editing Stocks to Buy in August 2024 - Markets Insider
Zerlasiran shows promise in phase 2 study for cardiovascular risk - Investing.com India
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? - Yahoo Finance
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - MSN
symbol__ Stock Quote Price and Forecast - CNN
Claire Keast-Butler - Cooley
Our approach to nucleotide-based therapeutics - AstraZeneca
Silence Therapeutics Plc ADR (SLN-Q) QuotePress Release - The Globe and Mail
5 Stocks to Buy as the Drug Industry Bets Big on Innovation - Nasdaq
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Genfit (NASDAQ:GNFT) Stock Quotes, Forecast and News Summary - Benzinga
Silence Therapeutics (SLN) - Zacks Investment Research
Silence Therapeutics Plc Adr (SLN) 財務データ
収益
当期純利益
現金流量
EPS
13.67%
大文字化:
|
ボリューム (24 時間):